A Phase II Study of Pre-Op SRS Followed by Surgical Resection for Brain Metastases
A Phase II Study of Pre-Operative Stereotactic Radiosurgery Followed by Surgical Resection for Brain Metastases
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Contact
- Phone Number: 412-330-6151
- Email: clinicaltrials@ahn.org
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologic proof or unequivocal cytologic proof of solid tumor malignancy. This may be obtained from either the primary site or any metastatic site
- Solid tumor brain metastases
- Age≥ 18 years
- Karnofsky Performance Status ≥70
- Patient must have agreed to undergo surgical resection to manage at least 1 brain metastasis
- Maximum tumor diameter of index lesions <5 cm. (Index lesion defined as the brain metastasis which will undergo surgical resection)
- Brain MRI within 1 month of initiation of brain SRS
- No prior whole brain radiotherapy (WBRT) or radiation therapy directed to index brain metastases
- Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
- Patient must have the ability to understand and the willingness to sign a written informed consent document
- All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
- Patients receiving prior SRS for brain metastases in other locations of the brain are eligible
- Patients with multiple brain metastases planned for surgical intervention are eligible for this study. Each individual brain metastasis will be treated
Exclusion Criteria:
- Prior WBRT or SRS to the index lesion
- Brain metastasis greater than or equal to (≤) 5 cm in maximum diameter
- Patients must not have a serious medical or psychiatric illness that would in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits.
- Karnofsky Performance Status (KPS) less than (<)70.
- Patients with absolute contraindication to MRI imaging are not eligible for the study
- Patients who are pregnant are excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pre-Operative Stereotactic Radiosurgery (SRS)
Subjects are treated using the standard of care SRS to a total dose of 24-27 Gray (Gy) in 3 fractions with a once daily fractionation or every other day at treating physician discretion.
The preferred dose will be 27 Gy, with ability to drop dose down to 24 Gy if normal tissue constraints cannot be met.
It should be noted, that while the dosing remains within standard of care, the timing of the radiation (pre-operative) is still not considered standard of care but is supported by emerging data as described in the study background.
Additional metastatic lesions may be treated using SRS according to institutional practices.
The radiation dose prescribed to the non-index lesions is at the discretion of the treating physicians.
Surgical resection will be performed within 2 weeks of completion of SRS.
|
Pre-operative SRS will be performed prior to the surgical resection of the brain metastases.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Radiographic Local Control
Time Frame: 4-5 Years from first subject enrolled.
|
Radiographic local control at 1 year following completion of pre-operative SRS followed by surgical resection of brain metastasis.
Local control will be according to the Response Assessment criteria for Neuro-Oncology (RANO) for brain metastases.
|
4-5 Years from first subject enrolled.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Leptomeningeal disease
Time Frame: 4-5 years from first subject enrolled.
|
MRI will be utilized to evaluate for evidence of leptomeningeal spread at 3 month intervals following preoperative SRS followed by surgical resection of the brain metastasis.
|
4-5 years from first subject enrolled.
|
|
Radio-Necrosis
Time Frame: 4-5 years from first subject enrolled
|
Pathologic confirmation of radio-necrosis will be recorded as binary variable for each patients as well as the date of surgery confirming radio-necrosis, as applicable.
|
4-5 years from first subject enrolled
|
|
Pseudo-Progression
Time Frame: 4-5 years from first subject enrolled
|
Defined as worsening T1 post-gadolinium contrast enhancement and fluid attenuated inversion recovery (FLAIR) changes following SRS which resolve independently without any intervention beyond steroids.
|
4-5 years from first subject enrolled
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Rodney E Wegner, MD, AHN Radiation Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-240-AGH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.